Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2

Brain Research

Volumn 1085, Issue 1, 2006, Pages 163-176

  Tagliaferro, Patricia ^a   Javier Ramos, Alberto ^a   Onaivi, Emmanuel S ^b   Evrard, Sergio Gustavo ^a   Lujilde, Javier ^a   Brusco, Alicia ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b WILLIAM PATERSON UNIVERSITY   (United States)

Author keywords

Cannabinoid receptor; GFAP; MAP 2; Neurofilament; Synaptic plasticity; Synaptophysin

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYTOSKELETON PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN 160; NEUROFILAMENT PROTEIN 200; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL STRUCTURE; CELL ULTRASTRUCTURE; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOSKELETON; DIGITAL IMAGING; DRUG MECHANISM; ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYNAPSE; ANIMAL; BRAIN; COMPARATIVE STUDY; CYTOLOGY; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; METABOLISM; METHODOLOGY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; WISTAR RAT;

ANIMALIA; RATTUS NORVEGICUS;

ANIMALS; BRAIN; CYTOSKELETAL PROTEINS; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MORPHOLINES; NAPHTHALENES; NEURONS; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; SYNAPSES; SYNAPTOPHYSIN;

EID: 33746878286     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.12.089     Document Type: Article

References (56)

1. Alger B. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68 (2002) 247-286
2. Alger B. Endocannabinoids in their implications for epilepsy. Epilepsy Curr. 4 5 (2004) 169-173
3. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58 (1999) 315-348
4. Azmitia E.C., Dolan K., and Whitaker-Azmitia P.M. S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor. Brain Res. 516 (1990) 354-356
5. De Lago E., Fernandez-Ruiz J., Ortega-Gutierrez S., Cabranes A., Pryce G., Baker D., Lopez-Rodriguez M., and Ramos A.J. UCM707, an inhibitor of the anadamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur. Neurophsychopharmacol. (2005) (electronic publication ahead of print)
6. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
7. Dove Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., and Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 51 (1998) 391-402
8. Evrard S., Duhalde Vega M., Ramos A.J., Tagliaferro P., and Brusco A. Altered neuron-glia interactions in a low chronic prenatal ethanol exposure. Dev. Brain Res. 147 1-2 (2003) 119-133
9. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 3 (2003) 1017-1066
10. Garcia G., Tagliaferro P., Bortolozzi A., Madariaga M.J., Brusco A., Evangelista de Duffard A.M., Duffard R., and Pecci Saavedra J. Morphological study of 5-HT neurons and astroglial cells on brain of adult rats perinatal or chronically exposed to 2,4-dichlorophenoxyacetic acid. Neurotoxicology 22 6 (2001) 733-741
11. Gederman G., and Lovinger D.M. Emerging roles for endocannabinoids in long-term synaptic depression. Br. J. Pharmacol. 140 (2003) 781-789
12. Gong J.P., Onaivi E.S., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Symposium on Cannabinoids (2005) 91 Burlington, VT
13. Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, T., Brusco, A., Uhl, G.R., in press. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res.
14. Grotenhermen F. Cannabinoids. Curr. Drug Targets CNS Neurol. Disord. 4 5 (2005) 507-530
15. Hampson R.E., and Deadwyler S.A. Role of cannabinoid receptors in memory storage. Neurobiol. Dis. 5 (1998) 474-482
16. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., and Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98 7 (2001) 3662-3665
17. Heyser C.J., Hampson R.E., and Deadwyler S.A. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264 (1993) 294-307
18. Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., and Price D.L. Neurofilament gene expression: a major determinant of axonal caliber. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3472-3476
19. Iversen L. Cannabis and the brain. Brain 126 (2003) 1252-1270
20. Jackson S.J., Pryce G., Diemel L.T., Cuzner M.L., and Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134 1 (2005) 261-268
21. Khaspekov L.G., Brenz Verca M.S., Frumkina L.E., Hermann H., Marsicano G., and Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. 19 (2004) 1691-1698
22. Kim D., and Thayer S.A. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J. Neurosci. 21 10 (2001) RC146
23. Karanian D.A., Brown O.B., Makriyannis A., Kosten T.A., and Bahr B.A. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J. Neurosci. 23 34 (2005) 7813-7820
24. Kimelberg H., and Katz D.M. High-affinity uptake of serotonin into immunocytochemically identify astrocytes. Science 228 (1985) 889-891
25. Kreitzer A.C., and Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29 (2001) 717-727
26. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., and Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 1-2 (2005) 96-107
27. Lawston J., Borella A., Robinson J.D., and Whitaker-Azmitia P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res. 877 (2000) 407-410
28. Lichtman A.H., Dimen K.R., and Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119Z (1995) 282-290
29. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., and Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 5642 (2003) 84-88
30. Martin B.R., Mechoulam R., and Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65 (1999) 573-595
31. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., and Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
32. 2+ influx through the N methyl-d-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res. 622 (1993) 79-85
33. Nixon R.A., and Sihag R.K. Neurofilament phosphorylation: a new look at regulation and function. Trends Neurosci. 14 11 (1991) 501-506
34. Onaivi E.S., Chakrabarti A., Gwebu E.T., and Chaudhuri G. Neurobehavioral effects of delta-9-THC and cannabinoid receptor gene expression in mice. Behav. Brain Res. 72 (1995) 115-125
35. Onaivi E.S., Leonard C.M., Ishiguro H., Zhang P.W., Zhicheng L., Akinshola B.E., and Uhl G.R. Endocannabinoids and cannabinoid receptor genetics. Prog. Neurobiol. 66 (2002) 307-344
36. Onaivi E.S., Ishiguro H., Sejal P., Meozzi P.A., Myers L., Tagliaferro P., Hope B., Leonard C.M., Uhl G.R., Brusco A., and Gardner E. Methods to study the behavioral effects and expression of CB2 cannabinoid receptors and its gene transcripts in chronic mild stress model of depression. In: Onaivi E.S. (Ed). Marijuana and Cannabinoid Research: Methods and Protocols (2006), The Humana Press Inc.
37. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. (1998), Academic Press, San Diego
38. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74 (1997) 129-180
39. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., and Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301 3 (2002) 1020-1024
40. Ramos A.J., Tagliaferro P., López E.M., Pecci Saavedra J., and Brusco A. Neuroglial interactions in a model of parachlorophenylalanine-induced serotonin depletion. Brain Res. 883 (2000) 1-14
41. Ramos A.J., Evrard S., Tagliaferro P., Tricárico M.V., and Brusco A. Cellular and molecular effects of chronic maternal ethanol exposure on hippocampal and striatal morphology in offspring. In: Ali S. (Ed). Mechanisms of Drugs of Abuse II. Ann. N. Y. Acad. Sci. vol. 965 (2002), New York Academy of Sciences 343-353
42. Ramos A.J., Rubio M.D., Defagot C., Hischberg L., Villar M.J., and Brusco A. The 5-HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction alter ischemic damage caused by cortical devascularization. Brain Res. 1030 2 (2004) 201-220
43. Reynolds E.S. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J. Cell Biol. 17 (1963) 208-212
44. Rodriguez de Fonseca F., Del Arco I., Martín-Calderón J.L., Gorriti M.A., and Navarro N. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol. Dis. 5 (1998) 483-501
45. Ronesi J., Gederman G.L., and Lovinger D.M. Disruption of endocannabinoid release and striatal long-term depression by postsypantic blockade of endocannabinoid membrane transport. J. Neurosci. 24 7 (2004) 1673-1679
46. Salzet M., Breton C., Bisogno T., and Di Marzo V. Comparative biology of the endocannabinoid system. Possible role in the immune response. Eur. J. Biochem. 267 (2000) 4917-4927
47. Shain W., Madelain V., Martin D.L., Kimelberg H.K., Perrone M., and Lepore R. Activation of beta-adrenergic receptors stimulates release of an inhibitory transmitter from astrocytes. J. Neurochem. 46 (1986) 1298-1303
48. Striem S., Bar-Joseph A., Berkovitch Y., and Biegon A. Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. Eur. J. Pharmacol. 338 (1997) 205-213
49. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215 (1995) 89-97
50. Tagliaferro P., Ramos A.J., Lopez E.M., Pecci Saavedra J., and Brusco A. Neural and astroglial effects of a chronic parachlorophenylalanine-induced serotonin synthesis inhibition. Mol. Chem. Neuropathol. 32 1-3 (1997) 195-211
51. Tagliaferro P., Duhalde-Vega M., Evrard S., Ramos A.J., and Brusco A. Alcohol exposure during adulthood induces neuronal and astroglial alterations on the hippocampal CA1 area. In: Ali S. (Ed). Cellular and Molecular Mechanisms of Drugs of Abuse II. Ann. N. Y. Acad. Sci. vol. 965 (2002), New York Academy of Sciences 334-342
52. Tsacopoulos M., and Magistretti P.J. Metabolic coupling between glia and neurons. J. Neurosci. 16 3 (1996) 855-877
53. Van der Stelt M., and Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromol. Med. 7 1-2 (2005) 37-50
54. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 5746 (2005) 329-332
55. Walz W. Role of glial cells in the regulation of the brain ion microenvironment. Prog. Neurobiol. 33 (1989) 309-333
56. Wilson R.L., and Nicoll R.A. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature 410 (2001) 588-592